phenindione (hedulin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Phenindione is an anticoagulant which functions as a Vitamin K antagonist. The drug was discontinued in USA, but still in use worldwide.   NCATS

Chemistry

  • SMILES: O=C1C(C(=O)C2=CC=CC=C12)C3=CC=CC=C3
  • InChIKey: NFBAXHOPROOJAW-UHFFFAOYSA-N
  • Mol. Mass: 222.2387
  • ALogP: 2.85
  • ChEMBL Molecules:
    aloxiprin  
    phenindione  
More Chemistry

Pharmacology

Alternative names

2-phenyl-1,3(2h)-indenedione | 2-phenyl-1,3-diketohydrindene | 2-phenyl-1,3-indandione | athrombon | danedion | dindevan | diophindane | emandione | fenhydren | fenindiona | fenindione | hedulin | hemolidione | indion | phenhydren | phenillin | phenindion | phenindione | phénindione | phenindionum | phenylindandione | phenylindanedione | phenylindione | pid | theradione

Organizations (5)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (2)


 

Pulmonary Embolism

Venous Thrombosis

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Atrial Fibrillation (Phase 3)

Atrial Flutter (Phase 3)

Cerebral Intraventricular Hemorrhage (Phase 3)

Cerebrovascular Disorders (Phase 3)

Hematoma, Subdural (Phase 3)

Hemorrhage (Phase 3)

Intracranial Hemorrhage, Hypertensive (Phase 3)

Intracranial Hemorrhages (Phase 3)

Pregnancy Complications (Phase 3)

Subarachnoid Hemorrhage (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue